Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Bandello, Francesco
Kuppermann, Baruch D.
Loewenstein, Anat
Article History
Received: 1 April 2021
Revised: 20 May 2021
Accepted: 20 May 2021
First Online: 22 June 2021
Competing interests
: AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; CONSULTANT: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. NK: None. NP: None